These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 32928795)
1. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795 [TBL] [Abstract][Full Text] [Related]
2. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P; Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928 [TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016 [TBL] [Abstract][Full Text] [Related]
5. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Casneuf T; Adams HC; van de Donk NWCJ; Abraham Y; Bald J; Vanhoof G; Van der Borght K; Smets T; Foulk B; Nielsen KC; Rusbuldt J; Axel A; Lysaght A; Ceulemans H; Stevenaert F; Usmani SZ; Plesner T; Avet-Loiseau H; Nijhof I; Mutis T; Schecter JM; Chiu C; Bahlis NJ Leukemia; 2021 Feb; 35(2):573-584. PubMed ID: 32457357 [TBL] [Abstract][Full Text] [Related]
6. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329 [TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC; Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560 [TBL] [Abstract][Full Text] [Related]
9. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767 [No Abstract] [Full Text] [Related]
10. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661 [TBL] [Abstract][Full Text] [Related]
11. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Bahlis NJ; Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Chung W; Lee K; Mouro J; Agarwal A; Reece D Leuk Lymphoma; 2022 Jun; 63(6):1407-1417. PubMed ID: 35133221 [TBL] [Abstract][Full Text] [Related]